Results 201 to 210 of about 61,554 (301)

Clinical Trial Highlights: Targeting Alpha-Synuclein

Journal of Parkinson's Disease, 2019
Kevin, McFarthing, Tanya, Simuni
openaire   +3 more sources

Exercise, exerkines, and muscle–brain crosstalk in Parkinson's disease

Neuroprotection, EarlyView.
Abstract Parkinson's disease (PD) is a progressive neurodegenerative disorder with motor and non‐motor symptoms, driven by dopaminergic loss and α‐synuclein accumulation. Beyond neurodegeneration, growing evidence highlights skeletal muscle health as a key determinant of prognosis, with sarcopenia and frailty contributing to greater disability, fall ...
Salomón Páez‐García, Edgar Alvarado, Alejandro Cuevas, Laura Valverde, Eduardo Salinas, Kevin O'Hara‐Veintimilla, María Cruz Rodríguez‐Oroz, Miguel Germán Borda   +7 more
wiley   +1 more source

Dermal Alpha-Synuclein Aggregation in Seed Amplification Assays for Parkinson's Disease Subtype Differentiation. [PDF]

Eur J Neurol
Vieregge M, Kuzkina A, Janzen A, Oertel WH, Sommerauer M, Volkmann J, Doppler K.   +6 more
europepmc   +1 more source

Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation–Energy Axis?

Phytotherapy Research, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by a preclinical stage that typically lasts for decades. Early on during this time, microglia react to pathological changes and become protective and even transiently delay neurodegeneration.
Sara Merlo, Cristiana Lucia Rita Lipari, Aurora Patti, Maria Angela Sortino   +3 more
wiley   +1 more source

SERS‐Based Nano‐ and Microsystems Toward Biomedical Applications

Small, EarlyView.
This review provides a current overview of nano‐ and microscale SERS‐based devices, encompassing all aspects from material design to practical applications. We highlight controlled SERS‐active architectures, including patterned substrates, nanorods, microspheres, micromotors, and microneedles, as well as combinations of these microfluidic systems.
Gohar Soufi, Tijana Maric, Isidro Badillo‐Ramírez, Juliane Fjelrad Christfort, Matteo Tollemeto, Carmen Milan Guimera, Casper Nisula, Giulia Zappalá, Laura De Vittorio, Marta Rubio‐Huertas, Sungyeong Kim, Ziqiao Li, Morten Bo Søndergaard Svendsen, Zhongyang Zhang, Anja Boisen   +14 more
wiley   +1 more source

Formation of Condition-Dependent Alpha-Synuclein Fibril Strain in Artificial Cerebrospinal Fluid. [PDF]

Adv Sci (Weinh)
Sniečkutė R, Šulskis D, Jocytė A, Venclovaitė U, Tamulytė R, Žiaunys M, Smirnovas V, Sakalauskas A.   +7 more
europepmc   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Interplay between lipid droplets and alpha-synuclein: implication in Parkinson's disease pathogenesis. [PDF]

Front Mol Neurosci
Idi W, Sheta R, Oueslati A.
europepmc   +1 more source

Cathepsin Oxidation Alters Alpha-Synuclein Processing [PDF]

Frontiers in Neurology, 2019
openaire   +3 more sources

Rethinking Mitochondrial Parkinson's Disease in the α‐Synuclein Seed Amplification Assays Era

Movement Disorders, EarlyView.
Marco Percetti, Vidal Yahya, Alessio Di Fonzo, Edoardo Monfrini   +3 more
wiley   +1 more source